Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials
In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume to Australia and China, and a pharmacy benefits executive weighs in on why short-term cost thinking is complicating GLP-1 coverage decisions.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Votes 10 to 3 in Favor of Replimune's Rp1 Efficacy Data
Pharmaceutical Executive Daily: Inizio Engage launches Connected Insights
Pharmaceutical Executive Daily: FDA Approves Viatris's Gwyn Lo
The Ron Lanton Report: The Human Bottleneck
Get summaries like this every morning.
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.